Patients with heart failure who receive a high-dose inactivated influenza vaccine have a decreased risk for hospitalization.
A study in Circulation: Heart Failure found that high-dose inactivated influenza vaccine (HD-IIV) is associated with reduced rates of hospitalizations related to laboratory-confirmed influenza, cardiorespiratory disease, cardiovascular disease, and heart failure in patients with heart failure.
The findings come from the DANFLU-2 trial, conducted in Denmark over three consecutive influenza seasons (2022-2023 to 2024-2025), which included individuals aged 65 and older randomly assigned to receive HD-IIV or standard-dose inactivated influenza vaccine (SD-IIV).
No direct quotes available in the text.
Author's summary: High-dose flu vaccine reduces hospitalization risk in heart failure patients.